Emmaus Life Sciences Inc (EMMA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2020 | 12-2019 | 12-2018 | 09-2018 | 09-2017 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 1,354 | -54,842 | -72,587 | -10,333 | -7,113 |
| Depreciation Amortization | 4,087 | 23,854 | 18,295 | 200 | 49 |
| Accounts receivable | 1,953 | -361 | -1,761 | -1 | -1 |
| Other Working Capital | -2,834 | 311 | 2,110 | -811 | 13 |
| Other Operating Activity | -7,011 | 26,515 | 48,309 | 1,905 | 2,260 |
| Operating Cash Flow | $-2,451 | $-4,523 | $-5,634 | $-9,039 | $-4,792 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 35,601 | 221 | 5,970 | N/A | N/A |
| PPE Investments | -15 | -60 | -94 | -55 | -128 |
| Net Acquisitions | N/A | -1,645 | N/A | -307 | N/A |
| Purchase Of Investment | -3,956 | 0 | -13,316 | N/A | -190 |
| Purchase Sale Intangibles | N/A | N/A | N/A | N/A | -2 |
| Other Investing Activity | -26,160 | 0 | 0 | 0 | -162 |
| Investing Cash Flow | $5,470 | $-1,484 | $-7,440 | $-362 | $-480 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | N/A | N/A | N/A | 4,260 | 145 |
| Debt Issued | 2,765 | 600 | 29,376 | N/A | N/A |
| Debt Repayment | -5,217 | -5,491 | -25,077 | -76 | -57 |
| Common Stock Issued | 142 | 8,775 | 1,386 | 985 | 10,463 |
| Common Stock Repurchased | N/A | N/A | -11,262 | N/A | N/A |
| Other Financing Activity | 0 | 0 | 0 | 2,037 | -149 |
| Financing Cash Flow | $-2,310 | $3,884 | $-5,577 | $7,206 | $10,402 |
| Exchange Rate Effect | 9 | -13 | 0 | N/A | N/A |
| Beginning Cash Position | 1,769 | 3,905 | 22,556 | 5,449 | 318 |
| End Cash Position | 2,487 | 1,769 | 3,905 | 3,255 | 5,449 |
| Net Cash Flow | $718 | $-2,136 | $-18,651 | $-2,194 | $5,131 |
| Free Cash Flow | |||||
| Operating Cash Flow | -2,451 | -4,523 | -5,634 | -9,039 | -4,792 |
| Capital Expenditure | -15 | -60 | -94 | -55 | -128 |
| Free Cash Flow | -2,466 | -4,583 | -5,728 | -9,094 | -4,920 |